Drug repurposing against coronavirus disease 2019 (COVID-19): A review.
J Pharm Anal
; 11(6): 683-690, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1386105
ABSTRACT
Since December 2019, severe acute respiratory syndrome coronavirus 2 has been found to be the culprit in the coronavirus disease 2019 (COVID-19), causing a global pandemic. Despite the existence of many vaccine programs, the number of confirmed cases and fatalities due to COVID-19 is still increasing. Furthermore, a number of variants have been reported. Because of the absence of approved anti-coronavirus drugs, the treatment and management of COVID-19 has become a global challenge. Under these circumstances, drug repurposing is an effective method to identify candidate drugs with a shorter cycle of clinical trials. Here, we summarize the current status of the application of drug repurposing in COVID-19, including drug repurposing based on virtual computer screening, network pharmacology, and bioactivity, which may be a beneficial COVID-19 treatment.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Topics:
Vaccines
/
Variants
Language:
English
Journal:
J Pharm Anal
Year:
2021
Document Type:
Article
Affiliation country:
J.jpha.2021.09.001
Similar
MEDLINE
...
LILACS
LIS